About
Technology
Issues
FAQ
Links
Official Page
Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.